PT  - JOURNAL ARTICLE
AU  - Izadi, Neda
AU  - Taherpour, Niloufar
AU  - Mokhayeri, Yaser
AU  - Ghorbani, Sahar Sotoodeh
AU  - Rahmani, Khaled
AU  - Nazari, Seyed Saeed Hashemi
TI  - The epidemiologic parameters for COVID-19: A Systematic Review and Meta-Analysis
AID  - 10.1101/2020.05.02.20088385
DP  - 2020 Jan 01
TA  - medRxiv
PG  - 2020.05.02.20088385
4099  - http://medrxiv.org/content/early/2020/05/06/2020.05.02.20088385.short
4100  - http://medrxiv.org/content/early/2020/05/06/2020.05.02.20088385.full
AB  - Introduction The World Health Organization (WHO) declared the outbreak to be a public health emergency and international concern and recognized it as a pandemic. The aim of this study was to estimate the epidemiologic parameters of novel coronavirus (COVID-19) pandemic for clinical and epidemiological help.Methods Four electronic databases including Web of Science, Medline (PubMed), Scopus and Google Scholar were searched for literature published from early December 2019 up to 23 March 2020. The “metan” command was used to perform a fixed or random effects analysis. Cumulative meta-analysis was performed using the “metacum” command.Results Totally 76 observational studies were included in the analysis. The pooled estimate for R0 was 2.99 (95% CI: 2.71-3.27) for COVID-19. The overall R0 was 3.23, 1.19, 3.6 and 2.35 for China, Singapore, Iran and Japan, respectively. The overall Serial Interval, doubling time, incubation period were 4.45, 4.14 and 4.24 days for COVID-19. In addition, the overall estimation for growth rate and case fatality rate for COVID-19 were 0.38% and 3.29%, respectively.Conclusion Calculating the pooled estimate of the epidemiological parameters of COVID-19 as an emerging disease, could reveal epidemiological features of the disease that consequently pave the way for health policy makers to think more about control strategies.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was supported by School of Public Health and Safety, Shahid Beheshti University of Medical Sciences grant number 23149. The funding agency did not play any role in the planning, conduct, and reporting or in the decision to submit the paper for publicationAuthor DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data of this study are available in appendix file